A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Kobayashi Kako Expected to Face Administrative Penalty This Fiscal Year, Biz Suspension Likely
January 12, 2021
-
BUSINESS Drug Makers, Wholesalers Boost WFH as Japan Declares Second Emergency
January 12, 2021
-
COMMENTARY Potential Reimbursement Challenges of Aducanumab Could Usher in Health Insurance Overhaul in Japan
January 8, 2021
-
REGULATORY PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
-
ORGANIZATION Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
-
ACADEMIA Japan Reports Mother-to-Infant Cervical Tumor Transmission via Amniotic Fluids
January 7, 2021
-
BUSINESS Drug Makers, Wholesalers Brace for Second Emergency Declaration in Japan
January 6, 2021
-
ORGANIZATION 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
-
REGULATORY Govt Eager to Roll Out 1st COVID-19 Vaccine by Late February; PM Says Pfizer’s Japan Data Ready by Month-End
January 5, 2021
-
COMMENTARY Japan Rushing to Build COVID-19 Vaccination Regime as 1st Approval Draws Near
December 28, 2020
-
TRENDS Top 10 PHARMA JAPAN Articles in 2020
December 28, 2020
-
BUSINESS AstraZeneca to Accelerate Growth of Forxiga with Heart Failure Use, Gets Head Start in Arena before Rival Jardiance
December 28, 2020
-
REGULATORY MHLW Approves Label Expansions for Olumiant, Gardasil, Lynparza and More
December 28, 2020
-
BUSINESS Kobayashi Kako Recalls 12 More APIs after On-Site Inspections
December 25, 2020
-
BUSINESS Daiichi Sankyo Espha Stops Supply of 3 APIs after Kobayashi Kako Mix-up
December 25, 2020
-
BUSINESS 49 APIs Listed in 2020, 10 Billion-Plus Yen Peak Sales Projected for 17: Jiho Tally
December 24, 2020
-
ACADEMIA Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
December 24, 2020
-
REGULATORY Results of On-Site Probe into Kobayashi Kako Due Out Early Next Year, MHLW Eyes Biz Suspension
December 24, 2020
-
BUSINESS Axcelead Looks to Unearth New Drugs from Takeda’s Legacy Assets, 5-Plus Collaborations Ongoing
December 23, 2020
-
BUSINESS Meiji, Again, Halts Supply of Kobayashi Kako-Made Drugs after On-Site Inspections
December 23, 2020
ページ
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…